AstraZeneca’s Brilinta recommended in draft NICE guidance

AstraZeneca ticagrelor-based anti-clotting drug Brilinta has been recommended in new draft guidance from the National Institute for Health and Care Excellence (NICE).

The UK regulator is provisionally recommending a 60 mg dose of the therapy taken twice a day for up to three years among people who have had a heart attack at least 12 months ago and who remain at high risk of having a further heart attack or stroke.

This lower-dose option is being endorsed for use beyond the initial 12-month period as a continuation of their previous ticagrelor treatment, with no interruption between the higher 90 mg dose and the reduced 60 mg regimen.

Brilinta is backed by a body of clinical evidence showing it can offer benefits for patients in this situation, helping to reduce the fear of heart attack recurrence that can have a serious negative impact on a person's quality of life.

Professor Carole Longson, NICE's health technology evaluation centre director, said: "In provisionally recommending ticagrelor, we are pleased to be able to increase the treatment options available to the many thousands of people who stand to benefit from it."

With? ?over? ?20? ?years? ?of? ?experience? ?within? ?the? ?pharmaceutical? ?market,? ?we? ?at? ?Zenopa? ?have? ?the knowledge,? ?skills? ?and? ?expertise? ?to? ?help? ?find? ?the? ?right? ?job? ?for? ?you.? ?To? ?find? ?out? ?more? ?about? ?the current? ?pharmaceutical? ?roles? ?we? ?have? ?available,? ?you? ?can? ?search? ?for? ?the? ?latest? ?job? ?roles, register? ?your? ?details,? ?or? ?contact? ?the? ?team? ?today.